Badrawi Sayed

Biography

For more than 25 years, Sayed Badrawi has helped guide numerous life science start-ups to success and has had major responsibilities at Fortune 100 companies. Badrawi joined PDS as CEO in 2013 and is focused on leading the organization into the biopharma R&D world of the 21st century — one driven by an explosion of data generated by translational science, personalized medicine and genome analysis. Prior to joining PDS, Badrawi was the director and head of new product marketing and business development at Mitsubishi Tanabe Pharma America, Inc. In his seven years at the company, he led all U.S. strategic marketing and commercialization activities for the company’s clinical portfolio of drugs in Phase I, II and III development including target product profile (TPP) development, clinical study design and commercial infrastructure planning. Prior to Mitsubishi, Badrawi held positions as vice president at several medical device companies focused on osteoporosis, health care IT and diagnostics. Earlier in his career he was a pharmaceutical marketing manager at Abbott Laboratories and analyzed new monoclonal antibody technologies at Eli Lilly. He started his career as a molecular biologist at Amgen where he was a key part of the team to first clone and express erythropoietin (EPO), one of the first biotech blockbuster drugs. Since 2010, Badrawi has also served as a board director for ISI Life Sciences, Inc., a development stage diagnostics company. He has an MBA from the University of Chicago Booth School of Business and an A.B. in microbiology and immunology from the University of California at Berkeley.

Research Interest

Toxicology